Table 1.
Characteristics | No intensive care use (n=1,715) |
Late intensive care use (n=47) |
P-value |
---|---|---|---|
Study year | 0.12 | ||
2007–2008 winter season | 21% | 30% | |
2008–2009 winter season | 39% | 26% | |
2009–2010 winter season | 40% | 44% | |
Age, mo | 0.04 | ||
<6 | 62% | 77% | |
≥6 | 38% | 23% | |
Sex | 0.77 | ||
Male | 60% | 57% | |
Female | 40% | 43% | |
Race | 0.59 | ||
White | 60% | 55% | |
Black | 26% | 26% | |
Other or missing | 14% | 19% | |
Hispanic ethnicity | 37% | 40% | 0.61 |
Gestational age, weeks | 0.20 | ||
<32 | 7% | 13% | |
32–36.9 | 17% | 17% | |
≥37 | 77% | 70% | |
Birth weight, pounds | 0.07 | ||
<5 | 12% | 21% | |
≥5 | 88% | 79% | |
Exposure to tobacco smoke | 13% | 17% | 0.39 |
Major relevant, comorbid medical disorder* | 21% | 24% | 0.66 |
Previously admitted overnight to a hospital (any cause) | 20% | 30% | 0.10 |
Kept in ICU, premature nursery, or any type of special care facility when born (%) | 25% | 36% | 0.09 |
When difficulty breathing began prior to index visit | 0.11 | ||
<24 hours or no difficulty breathing | 29% | 38% | |
1–3 days | 43% | 47% | |
≥4 days | 28% | 15% | |
Vital signs on first day of admission | |||
Highest respiratory rate, per minute (median, IQR) | 52 (44–60) | 56 (48–70) | 0.003 |
<70 | 92% | 70% | <0.001 |
≥70 | 8% | 30% | |
Lowest O2 saturation on room air†, % (median, IQR) | 94 (92–96) | 91 (87–95) | 0.003 |
Given nebulized albuterol on first day of admission | 34% | 55% | 0.003 |
Given nebulized epinephrine on first day of admission | 7% | 19% | 0.01 |
Given steroids on first day of admission | 15% | 21% | 0.28 |
Received high flow oxygen on first day of admission | 2% | 21% | <0.001 |
Virology results of nasopharyngeal aspirate‡ | |||
RSV | 72% | 72% | 0.95 |
HRV | 25% | 28% | 0.71 |
Adenovirus | 8% | 11% | 0.59 |
HMPV | 8% | 9% | 0.78 |
Number of viral pathogens detected from nasopharyngeal aspirate | 1.00 | ||
0 | 5% | 4% | |
1 | 65% | 66% | |
≥2 | 30% | 30% |
Abbreviations: IQR, interquartile range; ICU, intensive care unit; RSV, respiratory syncytial virus; HRV, human rhinovirus; HMPV, human metapneumovirus.
Relevant comorbid medical disorders include respiratory, cardiac, neurologic, gastrointestinal, and immunologic diseases.
Data are available for 1401 patients.
Percentages do not sum up to 100% because of co-infections.